Información del producto
- Carbamic acid, N-[(1S)-1-[[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-6-yl]-9H-fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl]carbonyl]-2-methylpropyl]-, methyl ester, (2S,3S)-2,3-dihydroxybutanedioate (1:1)
Ledipasvir D-tartrate is a synthetic, broad-spectrum antiviral agent that is used to treat hepatitis C virus (HCV) infection. It inhibits the HCV NS5A protein, which is needed for viral replication and assembly. Ledipasvir D-tartrate was discovered by scientists at Gilead Sciences. The drug was approved for use in combination with sofosbuvir in 2017 as an oral treatment for chronic HCV infection.
Ledipasvir D-tartrate binds to the NS5A protein and blocks its ability to function, thereby inhibiting viral replication. Ledipasvir D-tartrate also prevents the production of new viruses by blocking the activity of other proteins needed for viral assembly and release from infected cells.
It is effective against a wide variety of microorganisms, including bacteria, fungi, and parasites. It has been shown to be active against methicillin-resistant Staphylococ
Propiedades químicas
Consulta técnica sobre: 3D-FL180961 Ledipasvir D-tartrate
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
